At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
FATE Fate Therapeutics
Post-Mkt 10-16 16:08:11 EDT
1.79
-0.13
-7.01%
盘后1.79
+0.000.00%
16:04 EDT
High1.98Low1.78Vol1.38M
Open1.94D1 Closing1.93Amplitude10.13%
Mkt Cap214.80MTradable Cap187.84MTotal Shares120.00M
T/O2.56MT/O Rate1.32%Tradable Shares104.94M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of Car T-Cell Therapies
THOMSON REUTERS  ·  10-12
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of Car T-Cell Therapies
Press Release: Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-Cell Therapies
Dow Jones  ·  10-12
Press Release: Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-Cell Therapies
Fate Therapeutics Reports New Employee Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  10-02
Fate Therapeutics Reports New Employee Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  10-02
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (FATE) Securities Case Faces Another Motion to Dismiss After 2025 Dismissal Order
TIPRANKS  ·  10-02
Fate Therapeutics (FATE) Securities Case Faces Another Motion to Dismiss After 2025 Dismissal Order
Fate Therapeutics to Join Jefferies, Piper Sandler Investor Healthcare Conferences
Reuters  ·  10-01
Fate Therapeutics to Join Jefferies, Piper Sandler Investor Healthcare Conferences
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
GlobeNewswire  ·  10-01
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
Sector Update: Healthcare Stocks Edge Higher Premarket Friday
MT Newswires Live  ·  09-25
Sector Update: Healthcare Stocks Edge Higher Premarket Friday
Fate Therapeutics - Receives $15 Mln Award for Phase 2 FT819 Trial in Lupus Nephritis
THOMSON REUTERS  ·  09-25
Fate Therapeutics - Receives $15 Mln Award for Phase 2 FT819 Trial in Lupus Nephritis
Fate Therapeutics Wins $15 Million CIRM Grant for FT819 Lupus Nephritis Phase 2 Trial
Reuters  ·  09-25
Fate Therapeutics Wins $15 Million CIRM Grant for FT819 Lupus Nephritis Phase 2 Trial
Fate Therapeutics Launches Phase 1/2 Complete Trial of FT839 Dual-CAR T Therapy in Rheumatoid Arthritis
Reuters  ·  09-16
Fate Therapeutics Launches Phase 1/2 Complete Trial of FT839 Dual-CAR T Therapy in Rheumatoid Arthritis
Fate Therapeutics announces clinical data from FT819 study
TIPRANKS  ·  09-09
Fate Therapeutics announces clinical data from FT819 study
Fate Therapeutics Presents Phase 1 Data for Off-the-Shelf CAR-T FT819 in Systemic Lupus Erythematosus at CCR-West 2026
Reuters  ·  09-09
Fate Therapeutics Presents Phase 1 Data for Off-the-Shelf CAR-T FT819 in Systemic Lupus Erythematosus at CCR-West 2026
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
GlobeNewswire  ·  09-09
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
Fate Therapeutics Joins Cantor Global Healthcare Conference Fireside Chat on FT819 Autoimmune CAR-T Program
Reuters  ·  09-03
Fate Therapeutics Joins Cantor Global Healthcare Conference Fireside Chat on FT819 Autoimmune CAR-T Program
Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial
TIPRANKS  ·  09-03
Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial
Fate Therapeutics intiates first patient in RECLAIM-LN trial
TIPRANKS  ·  08-16
Fate Therapeutics intiates first patient in RECLAIM-LN trial
Fate Therapeutics Price Target Maintained with a $7.00/Share by Wedbush
Dow Jones  ·  08-14
Fate Therapeutics Price Target Maintained with a $7.00/Share by Wedbush
Fate Therapeutics - Patients to Receive Single 900 Mln-Cell Dose of Ft819; Primary Endpoint at Week 26
THOMSON REUTERS  ·  08-14
Fate Therapeutics - Patients to Receive Single 900 Mln-Cell Dose of Ft819; Primary Endpoint at Week 26
Fate Therapeutics Initiates Potentially Registrational Reclaim-Ln Clinical Trial of FT819 for the Treatment of Lupus Nephritis
THOMSON REUTERS  ·  08-14
Fate Therapeutics Initiates Potentially Registrational Reclaim-Ln Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Introduction

Company Name.
Fate Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Issue price:
--